vs

Side-by-side financial comparison of Q2 Holdings, Inc. (QTWO) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Q2 Holdings, Inc. is the larger business by last-quarter revenue ($216.5M vs $207.3M, roughly 1.0× Ultragenyx Pharmaceutical Inc.). Q2 Holdings, Inc. runs the higher net margin — 12.3% vs -62.0%, a 74.3% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 14.1%). Q2 Holdings, Inc. produced more free cash flow last quarter ($44.2M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 11.9%).

Q2 Holdings, Inc. is a global financial technology firm that develops cloud-based digital banking platforms. It serves regional banks, credit unions, and other financial institutions, enabling them to offer secure online and mobile banking experiences to retail and business customers, with core operations based in North America.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

QTWO vs RARE — Head-to-Head

Bigger by revenue
QTWO
QTWO
1.0× larger
QTWO
$216.5M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+11.8% gap
RARE
25.9%
14.1%
QTWO
Higher net margin
QTWO
QTWO
74.3% more per $
QTWO
12.3%
-62.0%
RARE
More free cash flow
QTWO
QTWO
$145.0M more FCF
QTWO
$44.2M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
11.9%
QTWO

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
QTWO
QTWO
RARE
RARE
Revenue
$216.5M
$207.3M
Net Profit
$26.6M
$-128.6M
Gross Margin
59.1%
Operating Margin
12.8%
-54.7%
Net Margin
12.3%
-62.0%
Revenue YoY
14.1%
25.9%
Net Profit YoY
460.5%
3.5%
EPS (diluted)
$0.40
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
QTWO
QTWO
RARE
RARE
Q1 26
$216.5M
Q4 25
$208.2M
$207.3M
Q3 25
$201.7M
$159.9M
Q2 25
$195.1M
$166.5M
Q1 25
$189.7M
$139.3M
Q4 24
$183.0M
$164.6M
Q3 24
$175.0M
$139.5M
Q2 24
$172.9M
$147.0M
Net Profit
QTWO
QTWO
RARE
RARE
Q1 26
$26.6M
Q4 25
$20.4M
$-128.6M
Q3 25
$15.0M
$-180.4M
Q2 25
$11.8M
$-115.0M
Q1 25
$4.8M
$-151.1M
Q4 24
$164.0K
$-133.2M
Q3 24
$-11.8M
$-133.5M
Q2 24
$-13.1M
$-131.6M
Gross Margin
QTWO
QTWO
RARE
RARE
Q1 26
59.1%
Q4 25
55.4%
Q3 25
54.0%
Q2 25
53.6%
Q1 25
53.2%
Q4 24
52.6%
Q3 24
50.9%
Q2 24
50.2%
Operating Margin
QTWO
QTWO
RARE
RARE
Q1 26
12.8%
Q4 25
8.1%
-54.7%
Q3 25
5.5%
-106.9%
Q2 25
5.0%
-64.8%
Q1 25
1.2%
-102.6%
Q4 24
-0.9%
-74.3%
Q3 24
-7.3%
-94.6%
Q2 24
-7.9%
-79.1%
Net Margin
QTWO
QTWO
RARE
RARE
Q1 26
12.3%
Q4 25
9.8%
-62.0%
Q3 25
7.5%
-112.8%
Q2 25
6.0%
-69.0%
Q1 25
2.5%
-108.5%
Q4 24
0.1%
-80.9%
Q3 24
-6.7%
-95.7%
Q2 24
-7.6%
-89.5%
EPS (diluted)
QTWO
QTWO
RARE
RARE
Q1 26
$0.40
Q4 25
$0.32
$-1.28
Q3 25
$0.23
$-1.81
Q2 25
$0.18
$-1.17
Q1 25
$0.07
$-1.57
Q4 24
$0.01
$-1.34
Q3 24
$-0.20
$-1.40
Q2 24
$-0.22
$-1.52

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
QTWO
QTWO
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$342.3M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$611.7M
$-80.0M
Total Assets
$1.2B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
QTWO
QTWO
RARE
RARE
Q1 26
$342.3M
Q4 25
$432.7M
$421.0M
Q3 25
$568.7M
$202.5M
Q2 25
$532.1M
$176.3M
Q1 25
$486.0M
$127.1M
Q4 24
$446.6M
$174.0M
Q3 24
$407.9M
$150.6M
Q2 24
$372.1M
$480.7M
Stockholders' Equity
QTWO
QTWO
RARE
RARE
Q1 26
$611.7M
Q4 25
$661.8M
$-80.0M
Q3 25
$622.9M
$9.2M
Q2 25
$584.3M
$151.3M
Q1 25
$545.5M
$144.2M
Q4 24
$517.8M
$255.0M
Q3 24
$495.1M
$346.8M
Q2 24
$480.7M
$432.4M
Total Assets
QTWO
QTWO
RARE
RARE
Q1 26
$1.2B
Q4 25
$1.3B
$1.5B
Q3 25
$1.4B
$1.2B
Q2 25
$1.4B
$1.3B
Q1 25
$1.3B
$1.3B
Q4 24
$1.3B
$1.5B
Q3 24
$1.3B
$1.5B
Q2 24
$1.2B
$1.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
QTWO
QTWO
RARE
RARE
Operating Cash FlowLast quarter
$56.3M
$-99.8M
Free Cash FlowOCF − Capex
$44.2M
$-100.8M
FCF MarginFCF / Revenue
20.4%
-48.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
2.11×
TTM Free Cash FlowTrailing 4 quarters
$196.1M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
QTWO
QTWO
RARE
RARE
Q1 26
$56.3M
Q4 25
$63.7M
$-99.8M
Q3 25
$45.6M
$-91.4M
Q2 25
$48.6M
$-108.3M
Q1 25
$43.5M
$-166.5M
Q4 24
$43.0M
$-79.3M
Q3 24
$43.3M
$-67.0M
Q2 24
$36.0M
$-77.0M
Free Cash Flow
QTWO
QTWO
RARE
RARE
Q1 26
$44.2M
Q4 25
$61.7M
$-100.8M
Q3 25
$42.9M
$-92.7M
Q2 25
$47.3M
$-110.7M
Q1 25
$42.7M
$-167.8M
Q4 24
$41.6M
$-79.5M
Q3 24
$40.9M
$-68.6M
Q2 24
$34.6M
$-79.0M
FCF Margin
QTWO
QTWO
RARE
RARE
Q1 26
20.4%
Q4 25
29.6%
-48.6%
Q3 25
21.3%
-58.0%
Q2 25
24.3%
-66.5%
Q1 25
22.5%
-120.5%
Q4 24
22.7%
-48.3%
Q3 24
23.3%
-49.2%
Q2 24
20.0%
-53.7%
Capex Intensity
QTWO
QTWO
RARE
RARE
Q1 26
Q4 25
1.0%
0.5%
Q3 25
1.3%
0.8%
Q2 25
0.7%
1.5%
Q1 25
0.4%
1.0%
Q4 24
0.8%
0.1%
Q3 24
1.4%
1.2%
Q2 24
0.8%
1.4%
Cash Conversion
QTWO
QTWO
RARE
RARE
Q1 26
2.11×
Q4 25
3.12×
Q3 25
3.03×
Q2 25
4.13×
Q1 25
9.16×
Q4 24
262.41×
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

QTWO
QTWO

Subscription$179.9M83%
Services and Other$18.8M9%
Transactional$17.8M8%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons